Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2012

Arcila Maria E, Chaft Jamie E, Nafa Khedoudja, Roy-Chowdhuri Sinchita, Lau Christopher, Zaidinski Michael, Paik Paul K, Zakowski Maureen F, Kris Mark G, Ladanyi Marc

Abstract excerpt

PURPOSE: Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR and KRAS mutations. The prevalence, clinicopathologic characteristics, prognostic implications, and molecular heterogeneity of HER2-mutated lung ADCs are not well established in U.S. patients. EXPERIMENTAL DESIGN: Lung ADC samples (N =...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Prevalence

Share to Protein Interaction Domains and Motifs

Share to Receptor, ErbB-2

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 22761469
DOI: 10.1158/1078-0432.CCR-12-0912
PMCID: PMC3865806

Genes

EGFR
KRAS
ALK
ERBB2
BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.PMID 22761469Read ↗

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.Semantic proximity Read ↗

Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.Semantic proximity Read ↗

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.Semantic proximity Read ↗

Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic PerspectivesSemantic proximity Read ↗

The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.Semantic proximity Read ↗

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging TherapiesSemantic proximity Read ↗

The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.Semantic proximity Read ↗

Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.Semantic proximity Read ↗

Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights.Semantic proximity Read ↗

Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.